Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001883111-22-000001
Filing Date
2022-04-04
Accepted
2022-04-04 16:44:55
Documents
1
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 3303
  Complete submission text file 0001883111-22-000001.txt   4860
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address RIVIUM WESTLAAN 142 CAPELLE AAN DEN LJSSEL P7 2909LD
Business Address RIVIUM WESTLAAN 142 CAPELLE AAN DEN LJSSEL P7 2909LD 31-104064349
PF Equity Holdings 2 B.V. (Reporting) CIK: 0001883111 (see all company filings)

State of Incorp.: P7 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 22803065